We recently spoke with Kevin Koo, PhD (Lead Assay Development Scientist, XING Technologies, Brisbane, Australia). Koo is also an Honorary Fellow of the University of Queensland Centre for Clinical Research. His work focuses on the multidisciplinary areas of molecular diagnostics development, translation and commercialization for precision oncology applications. In this peek behind the paper, Koo gives an insight into his recent article published in Breast Cancer Management, discussing the use of liquid biopsies in breast cancer.
To view the full article, please register now for access